AIVITA Biomedical Named 2026 Prix Galien USA “Best Startup” Nominee for Personalized Immunotherapy Innovation
AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines and immunotherapies for infectious diseases and cancer, has been named a 2026 Prix Galien USA nominee in the “Best Startup” category, recognizing the company’s efforts to develop individualized immune-based technologies designed to address significant unmet medical needs.
The nomination places AIVITA among a group of innovative biotechnology companies being recognized for scientific and technological approaches that could contribute to advances in human health. The Prix Galien USA Awards, presented by The Galien Foundation, recognize achievements in biopharmaceutical research and medical innovation and have become an important platform for highlighting emerging technologies with the potential to influence future healthcare.
The winners of the 2026 Prix Galien USA Awards are scheduled to be announced at the awards ceremony on October 29, 2026, at the American Museum of Natural History in New York City. The Best Startup category specifically highlights younger companies whose scientific platforms and technologies demonstrate the potential to make a meaningful impact on medicine.
For AIVITA, the nomination represents recognition of its broader strategy to develop personalized approaches to both cancer treatment and infectious disease prevention. The company is building its technology around the concept of precision immunology, using a patient’s own immune cells and disease-specific antigens to create individualized immune responses.
Recognition for Personalized Immunology
AIVITA CEO Dr. Hans S. Keirstead said the company was honored to be recognized by The Galien Foundation alongside other innovators working to address important healthcare challenges.
“We are honored to be recognized by The Galien Foundation among an exceptional group of innovators,” said Dr. Keirstead. “This nomination reflects the dedication of our team and the potential of our personalized dendritic-cell platform to address urgent unmet needs in cancer and infectious disease.”
He added that AIVITA’s objective is to make advanced patient-specific immunotherapies increasingly practical, scalable and accessible to patients worldwide.
The company’s approach is based on an autologous dendritic-cell platform, meaning that immune cells are obtained from the individual patient and incorporated into the development of a personalized therapeutic or vaccine approach. Dendritic cells play a central role in the immune system by processing antigens and helping activate immune responses against foreign or abnormal cells.
By using these cells in a personalized manner, AIVITA aims to develop therapies capable of stimulating the immune system against disease-specific targets.
Targeting the Full Cancer Antigen Repertoire
A major area of AIVITA’s research is cancer immunotherapy. The company’s proprietary platform is designed to use antigens derived from a patient’s own tumor-initiating cells.
Tumor-initiating cells are considered an important population within certain cancers because of their ability to contribute to tumor growth and persistence. AIVITA’s strategy seeks to expose the patient’s immune system to a broad collection of antigens associated with these cells rather than relying on a single cancer-associated target.
This approach is described by the company as pan-antigenic, reflecting its objective of targeting a broad repertoire of antigens specific to an individual patient’s cancer.
The concept is particularly relevant to personalized cancer treatment because tumors can be biologically complex and can contain multiple populations of cancer cells with different molecular characteristics. Targeting several antigens simultaneously may provide researchers with an opportunity to develop broader immune responses than approaches focused on a single molecular target.
AIVITA is advancing this technology through investigational clinical programs in glioblastoma, melanoma and other solid tumors.
Glioblastoma represents a particularly challenging area of oncology research. It is an aggressive brain cancer associated with significant treatment challenges, and researchers continue to investigate new therapeutic approaches that could improve outcomes for patients.
Melanoma has also become an important field for immunotherapy development, with immune checkpoint inhibitors and other immune-based treatments demonstrating the potential of activating the immune system against cancer. AIVITA’s personalized dendritic-cell approach represents a different strategy focused on creating an individualized immune response based on the patient’s own tumor biology.
Personalized Vaccine Technology for Infectious Diseases
While cancer is a major focus of AIVITA’s technology, the company is also applying its personalized immunology expertise to infectious disease.
The same underlying technology supports AIVITA’s Clean Super Vaccine platform, which is being developed as a personalized, multi-pathogen vaccine system. The platform is designed to combine a patient’s own antigen-presenting cells with recombinant antigens derived from multiple pathogens.
The objective is to create a flexible vaccine platform that can potentially be adapted to different infectious disease threats.
According to AIVITA, the Clean Super Vaccine platform has already been evaluated clinically in the context of COVID-19. The company is now seeking to advance the technology toward broader applications in infectious disease preparedness.
The ability to respond rapidly to emerging infectious diseases has become an increasingly important consideration for governments, healthcare organizations and biotechnology companies. New pathogens can emerge quickly, while conventional vaccine development and manufacturing processes can require significant time and infrastructure.
AIVITA’s platform is being developed with an emphasis on point-of-care production and global accessibility, which could potentially support more flexible vaccine manufacturing approaches in different healthcare settings.
Addressing Global Healthcare Needs
The company’s strategy extends beyond developing individual therapies or vaccines. AIVITA is seeking to establish a platform capable of supporting personalized immunological interventions across multiple disease categories.
In cancer, the focus is on using patient-specific tumor antigens to educate the immune system to recognize and respond to malignant cells. In infectious disease, the company is exploring how the same cellular technology can be paired with recombinant pathogen antigens to create personalized multi-pathogen vaccines.
This common technological foundation could potentially allow AIVITA to apply its expertise across different therapeutic areas while maintaining an emphasis on individualized immune responses.
The company believes that making personalized immunotherapies scalable will be an important component of expanding access to these types of treatments. Personalized medicine has historically faced challenges related to manufacturing complexity, cost, turnaround time and the need to coordinate treatment development with individual patient characteristics.
AIVITA’s stated goal is to address some of these challenges by developing processes that can make patient-specific immune therapies more practical for broader use.
Prix Galien Recognition Highlights Scientific Potential
The 2026 Prix Galien USA nomination provides external recognition of AIVITA’s technology and its potential role in the future of personalized medicine.
The Prix Galien Awards are intended to highlight innovations that demonstrate significant scientific achievement and the potential to improve patient care. The Best Startup category is particularly relevant to emerging biotechnology companies because it provides an opportunity to recognize organizations developing new technologies that may eventually reshape therapeutic or healthcare practices.
For AIVITA, the nomination highlights the company’s work at the intersection of immunology, biotechnology and personalized medicine.
Dr. Keirstead emphasized that the company views the recognition as part of a broader mission to advance precision immunology.
“The Prix Galien USA Awards celebrate innovations that can reshape medical practice and improve lives,” he said. “We are proud that AIVITA’s approach to precision immunology has been recognized as part of that important mission.”
Continuing Development of the Platform
Although the Prix Galien nomination represents an important milestone, AIVITA’s technologies remain focused on ongoing research and clinical development. Its personalized dendritic-cell platform is being investigated in cancer, while the Clean Super Vaccine platform is being advanced for infectious disease applications.
The company’s approach reflects a broader trend within biotechnology toward developing platforms rather than isolated products. Platform technologies can potentially be adapted to multiple diseases by changing the relevant antigenic targets while maintaining core manufacturing or biological processes.
In AIVITA’s case, the underlying strategy centers on antigen-presenting cells and the immune system’s ability to recognize disease-associated antigens. The company is exploring how this principle can be used in different contexts, from patient-specific cancer immunotherapy to multi-pathogen vaccine development.
The upcoming Prix Galien USA ceremony will provide an opportunity for AIVITA and other nominees to showcase their approaches to scientific innovation. Regardless of the final award outcome, the nomination gives the company visibility among researchers, pharmaceutical and biotechnology professionals, investors and healthcare stakeholders interested in emerging medical technologies.
With its focus on personalized cancer vaccines, infectious disease preparedness and scalable immunological technologies, AIVITA Biomedical is continuing to pursue a strategy aimed at making precision immunology more accessible. The company’s 2026 Prix Galien USA “Best Startup” nomination recognizes that effort and highlights the potential of its technology to contribute to the next generation of personalized treatments and vaccines.
About the Prix Galien USA Awards
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve human health. Established in Paris in 1970, the Prix Galien honors the collaborative, multidisciplinary progress that defines modern biopharmaceutical innovation. The 2026 Prix Galien USA Awards mark 20 years of recognizing breakthroughs in medical technology, digital health and entrepreneurship. For more information, visit www.galienfoundation.org.
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient’s cancer.
Our patient-specific cancer treatments have shown great promise including eradicating tumors, without harmful side effects in melanoma, and renal cell cancer, and prolonging progression-free survival in glioblastoma. Our multi-pathogen vaccine kit for infectious diseases is targeted to emerging nations enabling point-of-care vaccine production in minimally equipped facilities by minimally trained third-party technicians.